Literature DB >> 3968117

Results of internal neurolysis of the median nerve for severe carpal-tunnel syndrome.

C E Rhoades, C A Mowery, R H Gelberman.   

Abstract

Thirty-six hands in thirty-two patients had internal neurolysis of the median nerve and carpal tunnel release for severe carpal-tunnel syndrome. Median-nerve function was evaluated in all hands using Weber two-point discrimination and electromyography. Thenar-muscle strength or bulk, or both, were recorded in thirty hands. Ten hands also had Semmes-Weinstein monofilament pressure-testing. The indication for neurolysis in these selected patients was the presence of any one of the following: an increase in two-point-discrimination values, thenar-muscle atrophy, or denervation potentials in the thenar muscles. Twenty-two (76 per cent) of the twenty-nine hands that had had diminished two-point discrimination preoperatively regained normal sensibility. Seven (70 per cent) of ten hands that had had thenar-muscle weakness (grade 3 or less) preoperatively regained grade-4 or 5 strength. Nine (50 per cent) of eighteen hands that had had thenar-muscle atrophy regained normal muscle bulk. Seventy-six per cent of the patients in this series recovered sensation and 70 per cent recovered muscle strength, and the procedure was well tolerated. Although no studies comparing the results of treatment of severe carpal-tunnel syndrome with and without internal neurolysis have been reported, we think that neurolysis, if it is done by a surgeon who is skilled in microsurgery, is a safe and effective procedure for severe carpal-tunnel syndrome.

Entities:  

Mesh:

Year:  1985        PMID: 3968117

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  9 in total

1.  Carpal tunnel and median nerve volume changes after tunnel release in patients with the carpal tunnel syndrome: a magnetic resonance imaging (MRI) study.

Authors:  T Crnković; V Trkulja; R Bilić; D Gašpar; R Kolundžić
Journal:  Int Orthop       Date:  2015-11-23       Impact factor: 3.075

Review 2.  Carpal tunnel syndrome: a review.

Authors:  F P Cantatore; F Dell'Accio; G Lapadula
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

3.  Mini-open versus extended open release for severe carpal tunnel syndrome.

Authors:  Praveen G Murthy; Peter Goljan; Gregory Mendez; Sidney M Jacoby; Eon K Shin; Arthur Lee Osterman
Journal:  Hand (N Y)       Date:  2015-03

4.  Chemically-induced chronic nerve compression in rabbits--a new experimental model for the carpal tunnel syndrome.

Authors:  H R Rosen; K Ammer; W Mohr; P Böck; G V Kornek; W Firbas
Journal:  Langenbecks Arch Chir       Date:  1992

5.  Recurrent carpal tunnel syndrome--analysis of the impact of patient personality in altering functional outcome following a vascularised hypothenar fat pad flap surgery.

Authors:  K Karthik; Rajesh Nanda; John Stothard
Journal:  J Hand Microsurg       Date:  2011-08-13

6.  The effect of epineurotomy on the median nerve volume after the carpal tunnel release: a prospective randomised double-blind controlled trial.

Authors:  Tomislav Crnković; Ranko Bilić; Vladimir Trkulja; Marijan Cesarik; Nikola Gotovac; Robert Kolundžić
Journal:  Int Orthop       Date:  2012-05-17       Impact factor: 3.075

7.  A case of carpal tunnel syndrome due to dialysis-related amyloidosis in a patient undergoing long-term hemodialysis.

Authors:  Y J Chung; K C Choi; J H Ha; K Y Kim; S C Lee; S W Kim; N H Kim; Y J Kang; E S Moon; M C Lee
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

Review 8.  Revision of Carpal Tunnel Surgery.

Authors:  Stahs Pripotnev; Susan E Mackinnon
Journal:  J Clin Med       Date:  2022-03-03       Impact factor: 4.241

9.  A new method of measuring the thumb pronation and palmar abduction angles during opposition movement using a three-axis gyroscope.

Authors:  Tomoyuki Kuroiwa; Koji Fujita; Akimoto Nimura; Takashi Miyamoto; Toru Sasaki; Atsushi Okawa
Journal:  J Orthop Surg Res       Date:  2018-11-16       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.